Literature DB >> 16127682

Prospective analysis of patients with adenocarcinoma of the gastric cardia and lymph node metastasis in the proximal field of the chest.

S M Lagarde1, H A Cense, J B F Hulscher, H W Tilanus, F J W Ten Kate, H Obertop, J J B van Lanschot.   

Abstract

BACKGROUND: The extent to which adenocarcinoma of the cardia with lymph node metastasis in the upper mediastinum is amenable to cure by radical surgery is open to debate. It remains unclear whether these relatively distant metastases have an effect on long-term survival. The aim of this study was to identify the incidence of such positive nodes and evaluate their prognostic significance.
METHODS: Some 50 patients with adenocarcinoma of the gastric cardia and substantial invasion of the oesophagus (junctional type II), who underwent an extended transthoracic oesophagectomy as part of a prospective randomized trial between 1994 and 2000, were studied.
RESULTS: Eleven patients (22 per cent) had lymph node metastasis in the proximal field of the chest. These patients had more positive nodes overall (P = 0.020) and a shorter median survival (P = 0.009) than those without such metastasis. Multivariate analysis identified positive nodes in the proximal field as an independent predictor of poor survival.
CONCLUSION: Lymph node metastasis in the proximal field of the chest is common and is an indicator of poor prognosis in patients with adenocarcinoma of the cardia.

Entities:  

Mesh:

Year:  2005        PMID: 16127682     DOI: 10.1002/bjs.5138

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study.

Authors:  Kazumasa Fujitani; Isao Miyashiro; Shoki Mikata; Shigeyuki Tamura; Hiroshi Imamura; Johji Hara; Yukinori Kurokawa; Jyunya Fujita; Kazuhiro Nishikawa; Yutaka Kimura; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Gastric Cancer       Date:  2012-08-16       Impact factor: 7.370

2.  Principles of esophageal cancer surgery, including surgical approaches and optimal node dissection (2- vs. 3-field).

Authors:  Philippe Nafteux; Lieven Depypere; Hans Van Veer; Willy Coosemans; Toni Lerut
Journal:  Ann Cardiothorac Surg       Date:  2017-03

3.  Extended lymphadenectomy in esophageal cancer is crucial.

Authors:  Daniel Tong; Simon Law
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

4.  Risk Factors and Prognostic Impact of Mediastinal Lymph Node Metastases in Patients with Esophagogastric Junction Cancer.

Authors:  Osamu Shiraishi; Takushi Yasuda; Hiroaki Kato; Mitsuru Iwama; Yoko Hiraki; Atsushi Yasuda; Masayuki Shinkai; Yutaka Kimura; Motohiro Imano
Journal:  Ann Surg Oncol       Date:  2020-05-14       Impact factor: 5.344

5.  Long-term survival following radical surgery after chemotherapy for esophagogastric adenocarcinoma with extensive lymph node metastases: report of a case.

Authors:  Yoshiro Aoki; Yasushi Toh; Junya Taomoto; Yoshihisa Sakaguchi; Takeshi Okamura
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

Review 6.  Western strategy for EGJ carcinoma.

Authors:  Simone Giacopuzzi; Maria Bencivenga; Jacopo Weindelmayer; Giuseppe Verlato; Giovanni de Manzoni
Journal:  Gastric Cancer       Date:  2016-12-30       Impact factor: 7.370

7.  Location of lymph node involvement in patients with esophageal adenocarcinoma predicts survival.

Authors:  Aaldert K Talsma; Chin-Ann J Ong; Xinxue Liu; Pieter van Hagen; Jan J B Van Lanschot; Huug W Tilanus; Richard H Hardwick; Nicholas R Carroll; Manon C W Spaander; Rebecca C Fitzgerald; Bas P L Wijnhoven
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

8.  Efficacy and safety of chemoradiation therapy compared with chemotherapy for esophageal carcinoma: An updated meta-analysis of randomized controlled trials.

Authors:  Jinyuan Liu; Lei Xue; Fuxi Zhen; Jinhua Luo
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.